APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
Ashley V. DiMarco(Duke University), James V. Alvarez(Fred Hutch Cancer Center), Kouros Owzar(Duke University), Sarah C. Van Alsten(Washington University in St. Louis), Nina Marie G. Garcia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jichun Xie(University of Minnesota), Melissa A. Troester(University of North Carolina at Chapel Hill), Brock J. McKinney(Duke University), Elizabeth A. Mendes(Duke University), Brent A. Hanks(Duke University), Jeremy Force(Daiichi Sankyo (Germany)), Xiaodi Qin(Duke Cancer Institute)
Cited by 67
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655